Overview
MaxCyte provides flow electroporation systems like ExPERT instruments for high-efficiency transfection of diverse cell types, from primary cells to billions in scale, supporting cell therapy, gene editing, protein production, and vaccine development. Their GMP-compatible platforms enable seamless scalability without re-optimization, ideal for R&D to manufacturing transitions in pharma and biotech. Applications include CRISPR engineering, CAR-mRNA expression, virus-like particles, and cell-based assays.
Frequently asked questions
- What cell types and scales can MaxCyte electroporation handle?
- MaxCyte systems transfect from 75,000 to 20 billion cells, including primary cells, immortalized lines, T cells, macrophages, HEK293T, and stem cells, with high efficiency and viability across small-scale R&D to GMP manufacturing.
- Is MaxCyte's technology GMP-compatible for clinical applications?
- Yes, platforms like ExPERT GTx are GMP-compatible, used for manufacturing virus-like particles with CRISPR-Cas9 RNPs and supporting cell therapy from discovery to Phase I.
- What therapeutic applications does MaxCyte support?
- MaxCyte enables cell therapy, gene editing (CRISPR), CAR-mRNA in Tregs, antibody/protein production, viral vectors, vaccines, and cell-based assays with scalable transient transfection.